Tyme Technologies Inc (TYME) gains 5.71% for July 21

Equities Staff  |

Tyme Technologies Inc (NASDAQ: TYME) shares gained 5.71%, or $0.06 per share, to close Wednesday at $1.11. After opening the day at $1.08, shares of Tyme fluctuated between $1.12 and $1.07. 698,305 shares traded hands a decrease from their 30 day average of 1,684,356. Wednesday's activity brought Tyme’s market cap to $191,149,652.

Tyme is headquartered in Bedminster, New Jersey..

About Tyme Technologies Inc

Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system. With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.

Visit Tyme Technologies Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Tyme Technologies Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Tyme Technologies Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content